ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 16.67 percent decrease over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $8.861 million which missed the analyst consensus estimate of $9.600 million by 7.70 percent. This is a 9.10 percent increase over sales of $8.122 million the same period last year.